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Abstract
Aims: A subpopulation of cancer cells, termed cancer stem cells (CSCs), has stemness properties, such as self-
renewal and differentiation, which drive cancer recurrence and tumor resistance. CSCs possess enhanced protection
capabilities to maintain reduced intracellular levels of reactive oxygen species (ROS) compared with nonstem-like
cancer cells. This study investigated whether reductive stress could regulate self-renewal activity in breast CSCs.
Results: We found that manifestation of stemness in breast cancer stem-like cells was associated with an
elevated production of reduced glutathione (GSH) maintained by upregulation of glutamate cysteine ligase
catalytic subunit (GCLC) and consequently, lowered ROS levels. This was accompanied by upregulation of
phospho-AMP-activated protein kinase, FoxO3a, and Bmi-1. Notably, expression of nuclear factor erythroid-
derived 2-like 2 (Nrf2) protein was substantially increased in cells undergoing sphere formation. We noticed that
expression of Bmi-1 was inhibited after introduction of Nrf2 short interfering RNA into MCF-7 mammosphere
cells. Silencing of Nrf2 expression suppressed the xenograft growth of subcutaneously or orthotopically injected
human breast cancer cells.
Innovation: Association between Nrf2 and self-renewal signaling in CSCs has been reported, but the under-
lying molecular mechanism remains largely unresolved. This study demonstrates the Nrf2-mediated signaling
pathway in maintenance of reductive stress in breast CSCs.
Conclusion: Nrf2 overactivation in breast CSCs upregulates GCLC expression and consequently enhances
GSH biosynthesis with concurrent reduction in intracellular ROS accumulation, thereby provoking the re-
ductive stress. The consequent upregulation of nuclear FoxO3a and its binding to the promoter of the gene
encoding Bmi-1 account for the self-renewal activity of breast cancer stem-like cells and their growth in a
xenograft mouse model. Antioxid. Redox Signal. 32, 1313–1329.
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Introduction
Cancer stem cells (CSCs) are defined as a small subsetof cells within the tumor microenvironment, which have
the intrinsic capability of self-renewal and differentiation (8).
The discovery of CSCs and elucidation of their role in cancer
recurrence have helped better understand tumor develop-
ment, metastasis, and resistance to chemo-/radiotherapy.
Some signaling molecules involved in the maintenance of
CSCs include Hedgehog, Notch, and Bmi-1 (6). Among
these, overexpression of Bmi-1 contributes to the manifes-
tation of the phenotype and self-renewal activity of CSCs in
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some solid tumors (23, 35). It also promotes epithelial–
mesenchymal transition and enhances tumorigenicity (31). In
pancreatic cancer cells, increased levels of Bmi-1 have been
found in tumor-initiating cell populations characterized by
the CD44+/CD24+/ESA+ marker, which contributes to CSC-
like invasive features (35).
It is noteworthy that CSCs maintain relatively low levels of
reactive oxygen species (ROS) (32). Diehn et al. have re-
ported that lower ROS levels in mammary CSCs might confer
their resistance to ionizing radiation (9). It is hence specu-
lated that low ROS content in CSCs is accompanied by dis-
turbances in cell cycle regulation, which may account for
their dormancy (42). Chen et al. found that treatment of he-
matopoietic stem cells with the antioxidant N-acetylcysteine
resulted in the acquisition of stemness characteristics (5).
In general, expression of cellular antioxidant defense pro-
teins is mainly regulated by the redox-sensitive transcription
factor, nuclear factor erythroid-derived 2-like 2 (Nrf2) (29).
Reduced glutathione (GSH) is a principal antioxidant mole-
cule responsible for the elimination of ROS. GSH production
is catalyzed by the glutamate cysteine ligase complex modifier
subunit and glutamate cysteine ligase catalytic subunit
(GCLC), under the control of Nrf2 (44). Recently, association
between Nrf2 and self-renewal signaling in CSCs has been
reported (38, 46, 49), but the underlying molecular mechanism
remains largely unresolved.
Forkhead box O (FoxO) family transcription factors func-
tion as cellular redox sensors. Their transcriptional activities
are affected by the alteration of intracellular and extracellular
redox status (21). FoxOs play a critical role in enhancing self-
renewal capability of stem cells (45). Bmi-1 is a key mole-
cule involved in the maintenance of stem cells as well as
cancer development (41). Here, we report that breast CSCs
maintain low levels of intracellular ROS by upregulating
Nrf2-induced expression of GCLC, thereby maintaining self-
renewal activity via the FoxO3a-Bmi1 axis.
Results
The intracellular redox status is critical
for the manifestation of stemness in breast cancer
stem-like cells
It has been reported that CSCs, in general, exhibit lower ROS
levels than nonstem cells (9, 39), which is maintained by up-
regulation of antioxidant gene expression. The correlation be-
tween recurrent breast cancer and antioxidant gene expression
was assessed by gene set enrichment analysis (GSEA) of clin-
ical data deposited from GSE2034. Through the GSEA analy-
sis, we found that the ROS-related gene set was significantly
enriched in breast tumor from nonrelapsed patients, whereas
biosynthetic and metabolic processes of ROS were down-
regulated in the relapsed breast cancer (Fig. 1A). When MCF-7
cells were grown as mammospheres for 5 days, the cellular ROS
level was found to be decreased compared with that in parent
cells as measured by fluorescence-activated cell sorting (FACS)
analysis (Fig. 1B and Supplementary Fig. S1A).
We isolated CD24low/CD44high breast cancer stem-like cells
from MCF-7 mammospheres by use of the FACSAria cell
sorter, and the intracellular accumulation of ROS was measured
by 2¢,7¢-dichlorofluorescein diacetate (DCF-DA) staining. We
observed that CD24low/CD44high breast cancer stem-like cells
contain low levels of ROS when compared with parent MCF-7
‰
FIG. 1. Intracellular ROS levels, GSH contents, and expression of GCLC are crucial for the self-renewal ability of
breast cancer stem-like cells. (A) GSEA demonstrated the regulation of the ROS-related signaling in breast cancer tissues
with or without relapse. (B) MCF-7 cells were grown as mammospheres for 5 days, and then intracellular ROS levels were
determined by FACS analysis of cells after DCF-DA staining. (C) The mammosphere cells were analyzed by FACS for
sorting the CD24low/CD44high breast cancer stem-like cells. The intracellular ROS levels were then compared by DCF-DA
staining in parent MCF-7 cells and MCF-7-derived CD24low/CD44high cells. (D) Parent MCF-7 cells and mammospheres
were incubated with DHE or MitoSOX for 30 min, washed thoroughly, and immediately analyzed by FACS. (E) After
sorting mammosphere cells using respective CD24 and CD44 antibodies, intracellular GSH levels and the GSH/GSSG ratio
were measured by using the GSH-Glo Glutathione Assay Kit. (F) The expression of CD44, GCLC, and Bmi-1 proteins
was analyzed by immunoblot analysis using total cell lysates with different CD24 and CD44 phenotypes sorted from
mammospheres. (G, H) MCF-7 mammosphere cells were treated with BSO or H2O2 at indicated concentrations. Total
protein extracts from mammosphere cells were subjected to Western blot analysis using anti-Bmi-1 antibody. Actin was
measured as an indicator of equal amounts of protein loaded. (I–K) MCF-7 cells were cultured on ultralow adherence plates
for 5 days to generate primary mammospheres. The primary mammospheres were dissociated and cultured for additional
5 days to generate secondary mammospheres. MCF-7 secondary mammosphere cells were treated with 0.1 mM BSO or
2 mM GSH-MEE for 3 days, and then the self-renewal capacity of MCF-7 cells was measured in terms of sphere formation.
Pictures are representative phase-contrast photomicrographs of mammospheres, and graph bars are presented as the number
of sphere cells (n = 3 per each treatment group, size >100 lm). Scale bar, 100 lm. BSO, buthionine sulfoximine; DCF-DA,
2¢,7¢-dichlorofluorescein diacetate; DHE, dihydroethidium; FACS, fluorescence-activated cell sorting; GCLC, glutamate
cysteine ligase catalytic subunit; GSEA, gene set enrichment analysis; GSH, reduced glutathione; GSH-MEE, glutathione-
reduced ethyl ester; GSSG, oxidized glutathione; H2O2, hydrogen peroxide; NES, normalized enrichment score; Nrf2,
nuclear factor erythroid-derived 2-like 2; ROS, reactive oxygen species. Color images are available online.
Innovation
Cancer stem cells (CSCs) possess enhanced protection
capabilities against oxidative stress induced by reactive
oxygen species (ROS) compared with nonstem-like can-
cer cells. In this study, we investigated whether reductive
stress could regulate self-renewal activity in breast CSCs.
The manifestation of stemness in CSC-like breast cancer
cells was associated with an elevated ratio of reduced/
oxidized glutathione and consequently, lowered ROS
levels. Therefore, activation of nuclear factor erythroid-
derived 2-like 2-mediated FoxO3a-Bmi1 signaling ac-
counts for self-renewal activity, and regulation of redox
status may provide therapeutic strategies in breast CSCs.


















































































































cells (Fig. 1C and Supplementary Fig. S1B). In general, super-
oxides in the cytoplasm and mitochondria are detected by using
dihydroethidium (DHE) and MitoSox dye, respectively (33). We
observed that mammospheres derived from MCF-7 cells exhi-
bited a decreased ROS level detected by DHE staining, whereas
MitoSox staining did not show any significant changes (Fig. 1D).
GSH is the most important hydrophilic antioxidant that
protects cells from exogenous and endogenous toxicants,
including ROS (4). The ratio of GSH to an oxidized form
(GSSG) has been considered as an indicator of cellular redox
status. Thus, the reduced ratio of GSH/GSSG is an indication
of oxidative stress, whereas an increased ratio is indicative of
reductive stress (4). We noted that CD24low/CD44high breast
cancer stem-like cells exhibit the higher GSH/GSSG ratio as
well as total intracellular GSH than CD24high/CD44low cells
sorted from MCF-7 mammospheres (Fig. 1E). In addition,
there was a concurrent increase of CD44, GCLC, and Bmi-1
protein expression in CD24low/CD44high breast cancer stem-
like cells (Fig. 1F and Supplementary Fig. S1C).
To further verify that the redox status in mammosphere
formation is essential for regulation of Bmi-1-mediated self-
renewal signaling, we performed the immunoblot analysis
using anti-Bmi1 antibody after the treatment of MCF-7
mammospheres with buthionine sulfoximine (BSO), an in-
hibitor of GCLC, and also with hydrogen peroxide (H2O2). As
shown in Figure 1G and H, treatment of mammosphere cells
with these compounds provoking prooxidant status resulted in
the decreased Bmi-1 protein expression (Supplementary
Fig. S1D, E), suggesting that the ROS production might render
these cells incompetent for self-renewal activity. Thus,
we intended to determine whether GCLC could regulate the
self-renewal activity in the process of generating the third-
generation mammospheres. Depletion of GSH by BSO treat-
ment led to a diminution of the number and the size of
mammospheres (Fig. 1I). In contrast, treatment of MCF-7
mammospheres with glutathione-reduced ethyl ester (GSH-
MEE), a membrane permeable derivative of GSH, resulted in
the increased size and the number of mammospheres (Fig. 1J).
Notably, the GSH-mediated increase in mammospheres was
abrogated by BSO treatment (Fig. 1K).
Furthermore, we examined the GCLC mRNA expression
levels in different CD24/CD44 phenotypes using a published
database (GSE2034). As shown in Supplementary Figure 2A,
the CD24low/CD44high group expressed higher amount of
GCLC than did the CD24high/CD44low group in breast cancer
patients. Further, GCLC expression correlated with poor
clinical outcome. In the GCLC-amplified group, the probabil-
ity of relapse-free survival was significantly higher than that in
the low GCLC expression group (Supplementary Fig. S2B).
To determine whether CD44 could be regulating the expres-
sion of GCLC transcripts in the patient tumor, we evaluated
trends in transcript abundance of each gene in the breast cancer
patients with relapse. Particularly, the correlation between
CD44 and GCLC significantly increased in relapse patient
samples of GSE1456 (Supplementary Fig. S2C).
GCLC-mediated GSH production upregulates
expression of FoxO3a and Bmi-1
in mammosphere cells
Recently, Hu et al. have reported that heterogeneity of
CSCs expressing different CD44 isoforms in breast cancer is
associated with a CSC subpopulation with enhanced lung
metastasis capacity (15). In line with this notion, there is an
increase in the expression of CD44s and CD44v types, GCLC
and Bmi-1 in third-generation mammospheres as compared
with parent cells (Fig. 2A and Supplementary Fig. S3A).
Sox-2 was used as a sphere cell marker. To determine the
possible involvement of GCLC in regulating the expression
of CD44 and Bmi-1 transcripts in patient tumor samples, we
evaluated trends in transcript abundance of each gene in the
breast cancer samples of GSE1456. As shown in Figure 2B,
GCLC expression was well correlated with the levels of
CD44 and Bmi-1 gene expression.
It has been demonstrated that overexpression of anti-
apoptotic proteins, such as Bcl-2, causes redistribution of
GSH to the nucleus, thereby altering the nuclear redox status
(24). Notably, nuclear GSH plays a role in regulating cellular
proliferation, and influences both telomerase activity and
histone function (12). To investigate the subcellular distri-
bution of GSH in breast cancer stem-like cells, mammo-
spheres were incubated with the 5-chloromethylfluorescein
diacetate fluorescent probe for 30 min. Next, the images were
taken by light microscopy to capture red fluorescence of
nuclei and green fluorescence for GSH. As illustrated in
Figure 2C, GSH was detected in the nucleus as well as cy-
toplasm of mammosphere cells.
It has been reported that FoxO activity is regulated by in-
tracellular GSH and ROS (13, 21). To determine whether in-
tracellular GSH can induce expression of FoxO3a, thereby
regulating Bmi-1, MCF-7 cells were treated with GSH-MEE
for 48 h. As shown in Figure 2D, exogenous supply of GSH
resulted in upregulation of FoxO3a and Bmi-1 (Supplementary
Fig. S3B). In contrast, expression of Bmi-1 and FoxO3a was
decreased in BSO-treated MCF-7 mammosphere cells (Fig. 2E
and Supplementary Fig. S3C). Moreover, mammosphere for-
mation was accompanied by FoxO3a phosphorylation at the
Ser 7 residue, and subsequently nuclear accumulation in MCF-
7 cells (Fig. 2F, G and Supplementary Fig. S3D).
GSH induces phosphorylation of AMP-activated
protein kinase and FoxO3a for self-renewal activity
of breast cancer stem-like cells
It has been reported that the crosstalk between AMP-
activated protein kinase (AMPK) and FoxO under metabolic
stress is essential for redox maintenance (48). We found that
there was a robust increase in phospho-AMPK (Thr172) and P-
FoxO3a (Ser7) in mammospheres compared with those in
parent MCF-7 cells (Fig. 3A, B and Supplementary Fig. S4A).
Ho et al. have reported that the Ser7 residue of FoxO3a is the
only phosphorylation site associated with its nuclear enrich-
ment (14). We found that levels of Bmi-1 protein expression
and FoxO3a phosphorylation were decreased in AMPK-
knockdown MCF-7 mammosphere cells (Fig. 3C and Sup-
plementary Fig. S4B). Further, phosphorylation of AMPK and
FoxO3a was markedly enhanced in MCF-7 mammosphere
cells treated with GSH-MEE (Fig. 3D and Supplementary
Fig. S4C). Conversely, treatment of GSH-enriched mammo-
spheres with the prooxidant H2O2 abrogated the AMPK acti-
vation (Fig. 3E and Supplementary Fig. S5A). Moreover,
treatment of mammosphere cells with H2O2 resulted in de-
creased expression of both total and phosphorylated FoxO3a
proteins (Fig. 3F and Supplementary Fig. S5B). These findings

























































FIG. 2. GCLC-mediated GSH generation induces increased Bmi-1 expression and nuclear distribution of FoxO3a
in mammosphere cells. (A) After the generation of mammospheres, expression of CD44, GCLC, and Bmi-1 proteins was
determined by immunoblot analysis in MCF-7 parent and sphere-forming cells. Sox-2 was used as a positive control to
ensure the mammosphere formation. The levels of total CD44 (CD44s and CD44v), GCLC, and Bmi-1 proteins were
normalized to actin, and the corresponding bands were quantified using the Multi Gauge version 3.0 program (Fujifilm).
Replicate measurements were typically performed in triplicate. Data are shown as mean values – SD. (B) Indicated gene
expression data from breast cancers were analyzed using the cBioportal web interface, and correlation plots with Spear-
man’s correlations are presented. GCLC expression was correlated with the levels of CD44 and Bmi-1 gene expression. (C)
Parent and mammosphere MCF-7 cells were incubated with the CMFDA probe for 30 min. The images were then taken by
light microscopy to capture red fluorescence for nuclei and green fluorescence for GSH. Scale bar, 200 lm (D, E) Primary
MCF-7 mammosphere cells were treated with or without 2 mM GSH-MEE or 0.1 mM BSO for 48 h, and total lysates were
prepared and subjected to Western blot analysis using antibodies against Bmi-1 and FoxO3a. Replicate measurements were
typically performed in triplicate (n = 3). (F) Nuclear protein levels of Foxo3a were determined in parent MCF-7 cells and
mammospheres by immunoblot analysis. a-Tubulin and Lamin B1 were used as molecular markers for the cytosolic and
nucleus fractions, respectively. (G) The nuclear FoxO3a protein level was determined by immunocytochemistry in parent
MCF-7 cells and MCF-7-derived sphere-forming cells. Scale bar, 200 lm. CE, cytosolic extract; CMFDA, 5-


























































suggest that a redox shift toward GSH accumulation can trigger
phosphorylation of AMPK and FoxO3a, which accounts for
self-renewal activity of breast cancer stem-like cells.
FoxO3a induces Bmi-1 transcription by directly binding
to its proximal promoter
After revealing the FoxO3a upregulation by GSH, we
determined whether FoxO3a could regulate the expression of
Bmi-1. We noticed that expression levels of Bmi-1 protein
and its mRNA transcript were decreased in FoxO3a knock-
down MCF-7 mammosphere cells (Fig. 4A, B and Supple-
mentary Fig. S6A). To understand how the Bmi-1 gene
expression is regulated by FoxO3a, we analyzed the Bmi-1
promoter region and identified a single putative FoxO3a
binding site in the upstream of the transcription start site. The
information on the promoter region (promoter ID: BMI1_2)
was obtained from a Eukaryotic promoter database. FoxO3a
binding to the Bmi-1 promoter was verified by a chromatin
immunoprecipitation (ChIP) assay (Fig. 4C).
In addition, the proportion of the CD44high/CD24low cell
population in MCF-7 mammospheres was decreased by
FIG. 3. Phosphorylation of AMPK and FoxO3a by GSH leads to the nuclear localization of FoxO3a. (A) After the
generation of mammospheres, expression of P-AMPK (Thr172) and total AMPK was determined by immunoblot analysis in
parent MCF-7 and mammosphere cells. (B) After the generation of mammospheres, expression of P-FoxO3a (Ser7) was
determined by immunocytochemistry in parent MCF-7 and mammosphere cells. Scale bar, 100 lm. (C) MCF-7 cells were
transfected with scrambled siRNA and AMPK-specific siRNA for 72 h, followed by sphere-forming culture for additional
5 days. Levels of P-FoxO3a and Bmi-1 were determined by Western blot analysis. Relative band intensity of indicated
proteins was normalized to actin, and the corresponding bands were quantified using the Multi Gauge. Replicate mea-
surements were typically performed in triplicate (n = 3). (D) Primary MCF-7 mammosphere cells were incubated with GSH-
MEE (2 mM) for 48 h. Whole lysates with or without GSH-MEE treatment were prepared and subjected to Western blot
analysis for measurement of P-AMPK (Thr172), P-FoxO3a (Ser7), and their respective total forms. (E) To determine the
phosphorylation of AMPK, MCF-7 mammosphere cells were incubated with GSH-MEE (2 mM) for 12 h and incubated with
H2O2 (200 lM) for another 24 h. (F) MCF-7 mammosphere cells were treated with H2O2 at indicated concentrations for
48 h. Mammosphere cells were harvested and subjected to immunoblot analysis. AMPK, AMP-activated protein kinase;
NC, negative control; P-AMPK, phospho-AMPK; siRNA, short interfering RNA. Color images are available online.

























































FIG. 4. FoxO3a induces Bmi-1 transcription in MCF-7 mammosphere cells. (A, B) MCF-7 cells were transfected with
scrambled siRNA or FoxO3a-specific siRNA for 72 h, followed by sphere-forming culture for additional 5 days. Levels of
FoxO3a and Bmi-1 were determined by Western blot (A) and/or RT-PCR analyses (B). (C) The left diagram illustrates the
Foxo3a binding site in the Bmi-1 promoter. Protein–DNA complexes from MCF-7 sphere cells were immunoprecipitated
with IgG or Foxo3a antibody. Binding of Foxo3a to the promoter region of Bmi-1 gene in MCF-7 mammosphere cells was
determined by the ChIP assay. (D) MCF-7 cells were transfected with respective specific siRNAs for 72 h, followed by
staining sphere-forming cells for additional 5 days with anti-CD44-APC and anti-CD24-PE antibodies. Flow cytometric dot
plots represent changes in the proportion of CD44high/CD24low cells. Quadrant analysis of fluorescence intensity of gated
cells in FL2 and FL4 channels was from 10,000 events. (E) MCF-7 cells were transfected with scrambled siRNA or
FoxO3a-specific siRNA for 72 h, followed by sphere-forming culture for additional 5 days. (F) MCF-7 cells were cultured
on ultralow adherence plates for 5 days to generate primary mammospheres. The primary mammospheres were dissociated
and cultured for additional 5 days to generate secondary mammospheres. MCF-7 secondary mammosphere cells were
treated with 10 lM compound C for 3 days, and then the self-renewal capacity of MCF-7 cells was measured in terms of
sphere formation. Sphere forming colonies were visualized by phase-contrast photomicrograph (magnification · 100) and
quantified. Pictures are representative phase-contrast photomicrographs of mammospheres, and graph bars are presented as
the mean percentage of sphere cells (n = 3 per treatment group, size >100 lm). Scale bar, 100 lm. ChIP, chromatin


























































knockdown of AMPK, Bmi-1, and FoxO3a using target-
specific short interfering RNA (siRNA) (Fig. 4D). Use of
unstained and singly dye-stained cells as compensation
controls is common, so we set the standard for flow cyto-
metry gating (Supplementary Fig. S6B). We also noticed
that knockdown of FoxO3a expression in MCF-7 cells
abrogated the formation of secondary mammospheres
(Fig. 4E). Treatment with compound C, a well-known in-
hibitor of AMPK, led to a diminution of the number and
the size of mammospheres (Fig. 4F). Furthermore, we per-
formed the correlation study with the breast cancer cohort of
early breast cancer patients (GSE1456, n = 159). The mod-
erate correlation between Foxo3a and Bmi-1 was found
(Supplementary Fig. S6C). Taken together, these findings
indicate that FoxO3a transcriptionally regulates Bmi-1 to
promote self-renewal activity of breast cancer stem-like
cells.
Nrf2 activation contributes to self-renewal
activity of breast mammosphere cells
Based on the upregulated expression of GCLC, we exam-
ined whether the Nrf2 signaling pathway could be activated
in breast cancer mammospheres. We observed that expression
of Nrf2 protein was substantially increased in cells growing
under sphere-forming conditions (Fig. 5A and Supplementary
Fig. S7A). In addition, the nuclear accumulation of Nrf2
was evident in the mammospheres derived from MCF-7
cells (Fig. 5B and Supplementary Fig. S7B), which was
further verified by immunocytochemical analysis (Fig. 5C).
Further, the sphere formation was abrogated by Nrf2 si-
lencing (Fig. 5C). As there was a concomitant increase in the
expression of CD44 and Nrf2 in third-generation mammo-
spheres, we explored the involvement of CD44 in self-
renewal activity via the Nrf2 signaling.
Variant forms of CD44 are likely to be involved in acti-
vation of Nrf2-mediated signaling (18). The expression of
Nrf2 was markedly inhibited in MCF-7 mammosphere cells
silenced for CD44 expression (Fig. 5D and Supplementary
Fig. S7C). Notably, the high levels of Nrf2 are significantly
related to relapsed breast cancer, according to the GSE2034
dataset (Fig. 5E). Collectively, these findings suggest that
activation of Nrf2 responsible for the GCLC upregulation in
breast cancer stem-like cells is attributable, at least in part, to
CD44. We found the decreased intracellular levels of GSH and
increased ROS production in Nrf2-knockdown breast cancer
(MDA-MB-231) cells. It is likely that reduced production of
GSH may provoke inefficient cellular detoxification of ROS in
Nrf2-silenced MDA-MB-231 cells (Fig. 5F, G).
Nrf2 plays a role in the sphere-forming capability
of breast cancer cells through upregulation
of GCLC and Bmi-1
Next, we examined the expression of Bmi-1 in Nrf2-
knockdown or overexpressing breast cancer cells. In general,
MDA-MB-231 cells exhibit a higher Nrf2 expression com-
pared with MCF-7 cells (47). As shown in Figure 6A, silencing
Nrf2 caused downregulation of the Bmi-1 expression in MDA-
MB-231 cells (Supplementary Fig. S8A). Conversely, over-
expression of Nrf2 enhanced the mRNA and protein levels of
Bmi-1 in MCF-7 cells (Fig. 6B and Supplementary Fig. S8B).
We also noticed that knockdown of Nrf2 expression in MCF-7
cells abrogated the formation of secondary mammospheres
(Fig. 6C). The proportion of CD44high/CD24low cell popula-
tion in MCF-7 mammospheres was decreased by knockdown
of Nrf2 using target-specific siRNA, whereas Nrf2 over-
expression induced stemness properties (Fig. 6D).
The human GCLC promoter contains the antioxidant re-
sponse element, which is the cis-acting consensus sequence
responsible for Nrf2 binding (26). We investigated whether
Nrf2 could upregulate GCLC expression in breast cancer
stem-like cells, necessary for their self-renewal activity me-
diated by Bmi-1 expression. For this purpose, two different
short hairpin RNAs (shRNAs) targeting Nrf2 were trans-
fected into MDA-MB-231 cells that constitutively express
Nrf2. Of these, the sh-Nrf2 (#2) efficiently lowered the levels
of Nrf2, GCLC, and Bmi-1 mRNA and protein in MDA-MB-
231 cells (Fig. 6E and Supplementary Fig. S8C). Likewise,
mammosphere formation was abolished in Nrf2-silenced
MDA-MB-231 cells (Fig. 6F). Moreover, expression of
GCLC and Bmi-1 as well as phosphorylation of AMPK and
FoxO3a was decreased in Nrf2-knockdown MDA-MB-231
cells (Fig. 6G and Supplementary Fig. S9). These results
suggest that Nrf2 overactivation upregulates GCLC, and
subsequently Bmi-1 responsible for self-renewal capability of
breast cancer stem-like cells.
Knockdown of Nrf2 attenuates the tumorigenicity
of breast cancer cells and mammospheres in vivo
To assess the oncogenic role of Nrf2 in the mammary
cancer progression, athymic nude mice were subcutaneously
injected with MDA-MD-231 cells transfected with either the
control or Nrf2-specific shRNA. In MDA-MB-231 xeno-
grafts, Nrf2-shRNA introduction suppressed the tumor
growth (Fig. 7A). Knockdown of Nrf2 significantly reduced
the size of tumors derived from MDA-MB-231 cells in the
xenograft mouse model (Fig. 7B). We confirmed reduced
Nrf2 expression by immunohistochemical (IHC) staining of
tumor tissues, and quantification of IHC image was per-
formed by ImageJ analysis (Fig. 7C and Supplementary
Fig. S10). It was accompanied by decreased expression of
GCLC, FoxO3a, and Bmi-1 proteins (Fig. 7D and Supple-
mentary Fig. S11).
In another experiment, MDA-MB-231 sphere-forming cells
transfected with lentivirus encoding Nrf2 shRNA or control
shRNA were transplanted orthotopically into the fourth in-
guinal mammary fat pads of female athymic nude mice. After
10 weeks of injection, the mice were anesthetized using iso-
flurane and in vivo tumor green fluorescence protein (GFP)
fluorescence was measured by the in vivo imaging system
(IVIS) spectrum computed tomography (CT). The mice
injected with control shRNA cells were able to form tumors
more rapidly than those with Nrf2-knockdown cells
(Fig. 7E). Overall morphology of the tumor was visualized
with hematoxylin and eosin staining (Supplementary
Fig. S12). IHC analysis showed a relatively weak staining of
Bmi-1 in tumor tissues of mice transplanted with Nrf2-
knockdown sphere-forming cells (Fig. 7F and Supplemen-
tary Fig. S13).
Discussion
There has been increasing evidence for a causal relation-
ship between intracellular redox status and manifestation of

























































stemness (9, 39). It has been known that CSCs maintain re-
duced levels of ROS compared with nonstem cells (30, 39).
CSCs retaining a low level of ROS exhibit elevated expres-
sion of stemness-associated molecules such as Notch-1 and
telomerase, which confers a self-renewal potential (16, 32).
Paul et al. have identified complex crosstalk between dy-
namic intracellular ROS flux and Nrf2 in the airway basal
stem cells, whereby Nrf2 activates the Notch pathway to
stimulate self-renewal activity (32). In addition, several re-
cent studies have revealed the role of Nrf2 in the manifes-
tation and maintenance of CSCs. Thus, the total expression
and nuclear translocation of Nrf2 increase under the sphere-
forming conditions, which enhance self-renewal activity (37,
38). However, it remains largely unresolved how the accu-
mulation of Nrf2 expression contributes to the self-renewal
activity. We also observed that the number and the size of
FIG. 5. The possible involvement of Nrf2 activation in breast mammosphere cells. (A) MCF-7 cells were cultured in
ultralow adherence plates for generating the third-generation mammospheres, and then expression of Nrf2 protein was
assessed by Western blot analysis. Relative band intensity of indicated proteins was normalized to actin, and the corre-
sponding bands were quantified using the Multi Gauge. Replicate measurements are typically performed in triplicate (n = 3).
(B, C) Nuclear Nrf2 protein levels were determined in parent MCF-7 cells and mammospheres by immunoblot analysis (B)
and immunocytochemistry (C). Tubulin and Lamin B1 were used as molecular markers for the cytosolic and nucleus
fractions, respectively. (D) MCF-7 cells were transfected with CD44 siRNA or negative control siRNA for 48 h, followed by
incubation for an additional 5 days to measure mammosphere formation. After sphere formation for 5 days, total cell lysates
from mammosphere cells were subjected to Western blot analysis to determine the expression of CD44 and Nrf2. (E) GSEA
enrichment plot of Nrf2 gene expression in breast cancer tissues with or without relapse. (F) Intracellular GSH levels in
control and Nrf2-shRNA expressing MDA-MB-231 cells were measured by using the GSH-Glo Glutathione Assay Kit. (G)
Control and Nrf2-shRNA expressing MDA-MB-231 cells were incubated with DCF-DA, and then the intracellular ROS
levels were measured by FACS analysis. shRNA, short hairpin RNA. Color images are available online.

























































FIG. 6. The effect of Nrf2 on the self-renewal activity of breast cancer cells. (A) MDA-MB-231 cells were transfected
with Nrf2-siRNA or scrambled siRNA for 72 h, and then the levels of Bmi-1 mRNA transcript and protein were assessed by
RT-PCR and Western blot analysis, respectively. (B) MCF-7 cells were transiently transfected with empty (MOCK) or Nrf2
overexpression vector, and Bmi-1 mRNA and protein expression was determined. (C) MCF-7 cells were transfected with
scrambled siRNA or Nrf2-specific siRNA for 72 h, followed by sphere-forming culture for additional 5 days. Sphere
forming colonies were examined by phase-contrast microscopy (magnification · 100). Pictures are representative photo-
micrographs of mammospheres, and graph bars are presented as the number of sphere cells (n = 3 per treatment group, size
>100 lm). Scale bar, 100 lm (D) MCF-7 cells were transfected with negative/Nrf2 siRNAs or MOCK/Nrf2 vector for 72 h,
followed by staining sphere-forming cells for additional 5 days with anti-CD44-APC and anti-CD24-PE antibodies. Flow
cytometric dot plots represent changes in the proportion of CD44high/CD24low cells. Quadrant analysis of fluorescence
intensity of gated cells in FL2 and FL4 channels was from 10,000 events. (E) Endogenous Nrf2 expression was inhibited by
two independent Nrf2-targeting shRNA lentiviruses (Nrf2-shRNA #1 or #2) in MDA-MB-231 cells. Efficiency of Nrf2
knockdown and its effect on the expression of GCLC and Bmi1 were assessed by RT-PCR and Western blot analysis. (F)
Control and Nrf2-shRNA expressing MDA-MB-231 cells were cultured on ultralow adherence plates for 5 days to generate
primary mammospheres, and then the primary mammospheres were dissociated and cultured for additional 5 days to
generate secondary mammospheres. Sphere forming colonies were examined by phase-contrast microscopy. Scale bar,



























































mammospheres derived from MCF-7 cells were reduced by
silencing Nrf2 as well as pharmacological inhibition of its
target protein, GCLC. In addition, ROS levels were found to
be decreased in the CD24low/CD44high breast cancer stem-
like cells compared with parent cancer cells. In accord with
these findings, we noticed a substantially elevated level of
intracellular GSH in breast cancer stem-like cells.
Mizuno et al. have shown that aldehyde dehydrogenase
(ALDH)-positive clear carcinoma cells retain a lower level of
ROS than cells with low ALDH activity, and that increased
FIG. 7. Knockdown of Nrf2 attenuates the tumorigenicity and self-renewal activity of breast cancer cells in vivo. (A) The
subcutaneous xenograft tumor growth of MDA-MB-231 cells with stable knockdown of Nrf2 was quantified with a manual
caliper two to three times per week and compared with that of control GFP-MDA-MB-231 cells. Values are means – SD.
*Significant difference between control and Nrf2 knockdown tumors at p < 0.05. (B) Established control GFP or Nrf2 knockdown
stable MDA-MB-231 cells were injected subcutaneously into the right and left side flanks of nude mice, respectively (n = 5 per
group). After 4 weeks, tumor GFP images were captured by the IVIS system. (C) Sections from xenograft tissues of mice injected
with MDA-MB-231 were immunostained for the Nrf2. (D) Whole tissue lysates were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and immunoblotted with GCLC, FoxO3a, and Bmi-1 antibodies. (E) One thousand cells from
established control GFP or MDA-MB-231 mammospheres stably silenced for Nrf2 expression were injected into their mammary
fat pad. After 10 weeks, bioluminescence images of mice bearing primary tumors were taken using an IVIS spectrum. (F) Sections
from mammary fat pad tissues injected with MDA-MB-231 mammospheres were immunostained for the Nrf2 and Bmi-1. GFP,
green fluorescence protein; IVIS, in vivo imaging system. Color images are available online.

























































HO-1 and SOD2 expression is regulated by Nrf2 (28). Notably,
Nrf2 can be a therapeutic target for chemoresistant breast cancer
cells and CSCs (38, 43). Syu et al. have reported that over-
expression of Nrf2 attenuates the apoptosis induced by cisplatin
in human breast cancer (MCF-7) cells under hypoxia, and the
drug resistance in Nrf2 overexpressing cells was decreased by
chemical inhibition of GCLC or its gene silencing (43).
Recently, Ryoo et al. reported that CD44 elevation led to
p62-associated Nrf2 activation in doxorubicin-resistant
MCF-7 cells (36). Autophagy activation might be an es-
sential cellular process for adaptation and survival of CSCs;
however, it is currently not clear how p62 is elevated by
autophagic alteration in CSCs (36). It will be important to
explore the relevance between autophagy and redox sig-
naling in CSCs. Autophagy can be initiated by increased
levels of ROS in various cancer cells, which triggers the
activation of Notch1, ALDH, and Nrf2 signaling. The role
of autophagy in cancer is still a double-edged sword. Bac-
tericidal antibiotics used in combination with an autophagy
blocker decreases tumor growth, whereas the use of an au-
tophagy inhibitor with the anticancer drug leads to increased
cell death (1, 34). In addition, many transcription factors
including NF-jB, HIF-1a, Nrf2, and Notch are regulated by
the cellular redox status. Kipp et al. observed that the acti-
vation of Nrf2, HIF, and NF-jB was induced throughout the
whole spheroids of colon cancer cells (20). Particularly, HIF
and Nrf2 are specifically activated in the core of larger
spheroids (20).
An intriguing question is how GSH that accumulates in
relatively large amounts in sphere-forming cells can mod-
ulate the self-renewal activity of breast cancer stem-like
cells. The alteration of nuclear redox conditions influences
chromatin conformation and stability. Glutathionylation of
histone H3 during the translocation of GSH into the nucleus
modulates the chromatin availability to replicative or tran-
scriptional machineries by affecting interactions between
H3 and nuclear proteins, such as lamin B receptor and
heterochromatin protein 1 (25). In addition, GSH functions
as an intracellular metal chelator (11). GSH supplementa-
tion improved lipid metabolism through increased expres-
sion of AMPK in skeletal muscles (3). Moreover, Dong
et al. have revealed that both oxidative stress and ROS in-
hibition can activate AMPK through different mechanisms
in a diabetic rat model. According to this study, AMPK
activation by low ROS is due to redox modification, spe-
cifically the S-glutathionylation of cysteine residues in its
alpha-subunit (10). It has been suggested that FoxO3a
phosphorylation by AMPK facilitates the recruitment of the
transcriptional complex at the specific target promoter.
AMPK activation is associated with an increase in NAD+
levels, leading to activation of SIRT1 and upregulation of its
downstream targets including FoxO3a (7). We speculate
that the regulation of FoxO3a by AMPK may play a crucial
role in fine-tuning of gene expression programs that control
redox balance.
It is widely accepted that FoxO3 is a key regulator of self-
renewal activity of stem cells depending on cellular redox
status (27). Loss of FoxO3 is associated with an increased
ROS level as well as decreased expression of SOD2 and
catalase (27). The results from our present study corroborate
the possible involvement of FoxO3a in reducing the intra-
cellular ROS levels, thereby conferring acquired self-
renewal capacity in breast CSCs. Doxorubicin-resistant
breast cancer cells show FoxO3a predominantly expressed
in the nucleus, which is then available for the phosphory-
lation of Akt (14). Notably, the Ser-7 residue of FoxO3a is
the only phosphorylation site associated with its nuclear
enrichment, thus providing a useful molecular marker of
nuclear FoxO3a (14).
FoxO3a is a transcription factor, which binds to a con-
sensus DNA sequence (G/C/A) (T/C/A) AAA (T/C) called
forkhead response element. FoxO3a regulates the transcrip-
tion of a wide variety of genes, such as Bim and Fas ligand
involved in regulating cell survival and death (2). In addition,
FoxO3a promotes the transcription of pluripotency factor
Nanog gene, and then stimulates enrichment of breast CSCs
(22). Interestingly, high expression of FoxO3 was associated
with poor prognosis in breast cancer patients who received
chemotherapy (22).
Dysregulated expression of Bmi-1 has been frequently
observed in several types of cancer (19, 40). Consistent with
our results, there has been correlation between Nrf2 accu-
mulation and Bmi-1 expression in cervical and gastric CSCs
(17, 49). Our study provides an insight into the mechanism
underlying upregulation of Bmi-1 expression by Nrf2 in
CSCs (Fig. 8). One of the most salient features of our
findings is that nuclear FoxO3a can directly bind to the
promoter of the gene encoding Bmi-1.
In conclusion, Nrf2-mediated upregulation of GCLC ex-
pression and GSH biosynthesis suppress intracellular ROS
accumulation. This, in turn, induces the nuclear localization
of FoxO3a, which binds to the Bmi-1 promoter, enhancing




Dulbecco’s modified Eagle’s medium (DMEM), Rosewell
Park Memorial Institute (RPMI) 1640 medium, and Dul-
becco’s modified Eagle’s Medium Nutrient Mixture F-12
(DMEM/F-12) were purchased from Gibco BRL (Grand Is-
land, NY). TRIzol, MitoSOX, DHE, and DCF-DA were
obtained from Invitrogen (Carlsbad, CA). Primary antibodies
for Bmi1, CD44, and Foxo3a were purchased from Cell
Signaling Technology (Danvers, MA). Primary antibody
against GCLC was obtained from Novus Biologicals (Lit-
tleton, CO). Primary antibodies against Nrf2 and b-actin were
purchased from Santa Cruz (Santa Cruz, CA). Antibodies
against CD24 and CD44 were purchased from BD Bios-
ciences (Bedford, MA). Bicinchoninic acid (BCA) protein
assay reagent was a product of Pierce Biotechnology
(Rockfold, IL). GSH-MEE, BSO, and H2O2 were purchased
from Sigma-Aldrich (St. Louis, MO).
Cell culture
Human breast cancer (MCF-7, MDA-MB-231) cell
lines were maintained in RPMI 1640 and DMEM medium
supplemented with 10% fetal bovine serum (FBS; GenDE-
POT, Barker, TX) and 100 ng/mL penicillin/streptomycin/
fungizone mixture at 37C in a humidified atmosphere of 5%
CO2/95% air.


























































MCF-7 (5 · 103 cells per well) and MDA-MB-231 (1 · 104
cells per well) cells were cultured in a serum-free DMEM/F12
medium supplemented with B27 (GIBCO), 20 ng/mL epider-
mal growth factor (Sigma-Aldrich), 20 ng/mL basic fibroblast
growth factor (Peprotech, Rocky Hill, NJ), and 4 ng/mL hep-
arin (Sigma-Aldrich) in six-well ultralow attachment surface
plates (Corning, NY). After 5 days, primary mammospheres
formation was examined using an inverted microscope. To
culture secondary mammospheres, primary mammospheres
were gently collected and dissociated into a single-cell sus-
pension using 40-lm strainer. Single cells were counted and
then seeded again for another 5 days with addition of 1 mL
medium every 2–3 days. After 5 days, secondary mammo-
spheres formation was examined using an inverted micro-
scope, and the number of mammospheres formed (>100 lm)
was quantified.
Flow cytometric analysis
MCF-7 cells were collected and washed with phosphate-
buffered saline (PBS), and dissociated with Accutase solution
(Sigma-Aldrich). Cells were then counted and washed with
PBS containing 2% FBS and 0.1% Tween-20. Cells were
stained with CD24-propidium iodide and CD44-APC from
BD Biosciences for 30 min at 4C. Cells were dissociated into
single cells by using 40-lm strainer, and then the population
of CD44+/CD24- cells was measured using BD FACSCalibur
(Becton Dickinson Biosciences, San Jose). To isolate CSC
and non-CSC populations from breast cancer cells, cells were
stained with the above antibodies, and the cells were sorted
using BD FACSAria III cell sorter (Becton Dickinson
Biosciences).
Determination of intracellular glutathione levels
Intracellular glutathione levels were determined using the
bioluminescent Promega GSH/GSSG-Glo assay kit (Pro-
mega, Mannheim, Germany) according to manufacturer’s
protocols. Luminescence was detected using SpectraMax i3
Multi-Mode Microplate Reader (Molecular Devices, Sun-
nyvale, CA).
Analysis of intracellular ROS accumulation
Intracellular accumulation of ROS was assessed by using
redox-sensitive dye DCF-DA. Cells were washed once with
Hanks’ balanced salt solution and loaded with 10 lM DCF-
DA for 30 min at 37C to assess ROS-mediated oxidation of
the fluorescent compound DCF. Fluorescence of oxidized
DCF was analyzed by flow cytometry.
Western blot analysis
Breast cancer cells were lysed in radioimmunoprecipitation
assay lysis buffer (150 mM NaCl, 0.5% Triton · 100, 50 mM
Tri-HCl (pH 7.4), 25 mM NaF, 20 mM EGTA, 1 mM dithio-
threitol, 1 mM Na3VO4, 0.1 mM PMSF, protease inhibitor
cocktail tablets) for 15 min on ice followed by centrifugation at
13,000 g for 20 min. The protein concentration of the super-
natant was measured by using BCA reagents (Thermo-
Scientific, Rockford, IL). Protein (30 lg) was separated by
running through 8%–12% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis gel and transferred to the
polyvinylidene fluoride membrane (Gelman Laboratory, Ann
Arbor, MI). The blots were blocked with 5% nonfat dry milk/
Tris-buffered saline buffer containing 0.1% Tween-20 (TBST)
for 1 h at room temperature. The membranes were incubated
overnight at 4C with indicated primary antibodies. The blots
were rinsed three times with TBST buffer for 10 min each.
Washed blots were incubated with 1:5000 dilutions of horse-
radish peroxidase-conjugated secondary antibody (Thermo-
scientific) for 1 h and washed again three times with TBST
buffer. The transferred proteins were visualized with an en-
hanced chemiluminescence detection kit (Amersham Phar-
macia Biotech, Buckinghamshire, United Kingdom).
Preparation of cytosolic and nuclear proteins
Cells were gently washed twice with ice-cold PBS, scraped
in 1 mL PBS and centrifuged at 12,000 g for 30 s at 4C.
Pellets were suspended in 200 lL of hypotonic buffer A
(10 mM HEPES, pH 7.9; 10 mM KCl; 2 mM MgCl2; 1 mM
DTT; 0.1 mM EDTA; 0.1 mM PMSF) for 15 min on ice, and
12.5 lL of 10% Nondiet P-40 solution was added for 5 min.
The mixture was then centrifuged for 6 min at 12,000 g,
FIG. 8. Schematic diagram illustrating stimulation of
self-renewal activity of breast cancer stem-like cells
through Nrf2-mediated GCLC upregulation. In breast
cancer stem-like cells, expression of CD44 induces nuclear
accumulation of Nrf2. Nrf2 upregulates GCLC expression by
binding to its promoter, and consequent overproduction of GSH
suppresses ROS accumulation. This, in turn, induces the acti-
vation of AMPK and FoxO3a through phosphorylation. FoxO3a
binds to the Bmi-1 promoter. In response to Nrf2 overactivation,
genes regulating the redox status are upregulated, which con-
tributes to the self-renewal activity and tumorigenesis. Color
images are available online.

























































washed once with 400 lL of PBS, and suspended in 70 lL of
buffer C (50 mM HEPES, pH 7.9; 50 mM KCl; 300 mM
NaCl; 0.1 mM EDTA; 1 mM DTT; 0.1 mM PMSF; and 10%
glycerol) for 20 min on ice and centrifuged for 6 min at
14,000 g. The supernatant containing nuclear proteins was
collected and stored at -70C after determination of the
protein concentration.
Immunofluorescence microscopy
To determine the localization of indicated proteins, we
adopted the immunocytochemical method that utilized a
monoclonal antibody recognizing Nrf2 and FoxO3a. Cells
(1 · 105 cells/600 lL in four-well chamber slides) were fixed
in 95% methanol/5% acetic acid solution for 10 min at
-20C. After a rinse with PBS, cells were blocked for 1h at
room temperature in fresh blocking buffer (0.5% Tween 20 in
PBS, pH 7.4, containing 10% normal goat serum). Dilutions
(1:100) of primary antibodies were made in PBS with 1%
bovine serum albumin, and cells were incubated overnight at
4C. After three washes with PBS containing 0.1% Tween 20
(PBST), the cells were incubated with FITC-conjugated
secondary antibody in PBST with 3% bovine serum albumin
for 1h at room temperature. Cells were rinsed with PBS, and
stained cells were analyzed under a fluorescence microscope
and photographed.
Reverse transcription-polymerase chain reaction
Total RNA was isolated from each cell by using TRIzol
reagent (Invitrogen) according to the manufacturer’s proto-
col. One microgram of total RNA was reverse transcribed
with murine leukemia virus reverse transcriptase (Promega,
Madison, WI). Polymerase chain reaction (PCR) was carried
out in a thermos-cycler using specific primers for Nrf2,
GCLC, Bmi-1, and GAPDH. The primers employed were
(forward and reverse, respectively): Nrf2, 5¢-ACTGGTT
GGGGTCTTCTGTG-3¢ and 5¢-CGGTATGCAACAGGAC
ATTG-3¢, 263 bp; GCLC, 5¢-TGAAGGGACACCAGG
ACAGCC-3¢ and 5¢-GCAGTGTGAACCCAGGACAGC-3¢,
167 bp; Bmi-1, 5¢-CCAGGGCTTTTCAAAAATGA-3¢ and
5¢-GCATCACAGTCATTGCTGCT-3¢, 271 bp; GAPDH, 5¢-
GCATGGCCTTCCGTGTCCCC-3¢ and 5¢-CAATGCCA
GCCCCAGCGTCA-3¢, 216 bp. Amplification products were
resolved by 1.5%–2% agarose gel electrophoresis, stained with
ethidium bromide and photographed under ultraviolet light.
Transient transfection of siRNA and plasmid
MCF-7 and MDA-MB-231 cells were plated at a conflu-
ence of 60% in 60-mm dish and grown in complete growth
media. Nrf2, CD44 and FoxO3a siRNA (25 nM) and Nrf2
plasmid were transfected into MCF-7 cells with lipofecta-
mine RNAiMAX or lipofectamine 2000 (Invitrogen) re-
agents. The siRNA sequences were (forward and reverse,





GAAGUUAGAACUG-3¢. Plasmid of pcDNA3.1-EGFP-C4-
human Nrf2 was obtained from Adggene (plasmid #21549).
ChIP assay
After formaldehyde crosslinking, cells were harvested, and
the ChIP assay was performed using EZ ChIP kit according to
the manufacturer’s protocol (Millipore). Chromatin was
immunoprecipitated with antibody against the FoxO3a or
IgG as a negative control. Input and bound DNA were
purified using the Genomic DNA Extraction Kit (SolGent,
Daejeon, Korea). PCR was performed against FoxO3a
binding region of the Bmi-1 promoter. The primer sequences
were 5¢-TTGTTTGGATCTGAGTTCGTGTG3¢ (forward)
and 5¢-ATCGCATCGTTTCCTCCGTG-3¢. Reaction condi-
tions were as follows: initial denaturation (5 min at 94C) was
followed by 40 cycles for 1 min at 94C, 1 min at 55C, and
1 min at 72C. PCR was completed by 10 min at 72C, and
products were separated on 2.5% agarose gel.
Knockdown of Nrf2 in breast cancer cells
A set of two human (SH-003755) specific SMART vector
2.0 lentiviral shRNA particles (108 TU/mL) for NFE2L2
were purchased from Thermo Fisher Scientific Dharmacon
(Lafayette, CO). The vector had an human cytomegalovirus
promoter, a TurboGFP reporter gene, and a puromycin se-
lection gene. SMART vector 2.0 nontargeting shRNA control
particles (108 TU/mL) were designed as a negative control.
MDA-MB-231 cells were cultured in DMEM with 10% FBS
in the presence of antibiotics, and viral particles (NFE2L2
and nontargeting control) were added with a multiplicity of
infection of 3.0 for cells. TurboGFP-expression was analyzed
using microscopy and GFP-positive cells selected using pu-
romycin (5 lg/mL). The selected cells were maintained in
culture media containing puromycin at 0.5 lg/mL until fur-
ther use. Nrf2 silencing was verified by Western blot and
mRNA quantification.
Mouse studies
Animal experiments were conducted in accordance with
Guide for the Care and Use of Laboratory Animals, and ap-
proved by the Institutional Animal Care and Use Committee of
Seoul National University (SNU protocol #160622-10). For a
xenograft tumor model, MDA-MB-231 (2 · 106 cells per
mouse in 50 lL containing Matrigel) was injected into 6-week-
old female BALB/c nu/nu mice. After 10 days, tumor volume
was determined by measuring the diameters of tumors with a
caliper every 2 or 3 days. Tumor volumes were calculated
according to the following formula: (length) · (width) ·
(height) · 0.52. For an orthotopic tumor model using mam-
mosphere cells, MDA-MB-231 mammosphere cells (1 · 105
cells per mouse in 50 lL containing Matrigel) were injected
into 6-week-old female nude mice at mammary fat pad.
Bioluminescence imaging was obtained by the IVIS spec-
trum micro CT and Living Image (ver. 4.2) software (Per-
kinElmer).
Public data resources
The clinical data of breast cancer were obtained from both
TCGA and GSE2034. The Cancer Genome Atlas (TCGA)
clinical data for breast cancer patients (n = 1108) were re-
trieved from cBioPortal, including RNA-seq gene expression
profiles. Dataset for recurrent breast cancer patients was

























































obtained from Gene Expression Omnibus. Gene expression
profiles of breast cancer from GSE2034 (nonrelapse [n = 179]
and relapse [n = 107]) and GSE1456 (nonrelapse [n = 119] and
relapse [n = 40]) were used for analysis.
Statistical analysis
When necessary, data were represented as means–SD of at
least three independent experiments, and statistical analysis
between groups was performed using Student’s t-test.
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DMEM¼Dulbecco’s modified Eagle’s medium
FACS¼ fluorescence-activated cell sorting
FBS¼ fetal bovine serum
FoxO¼ Forkhead box O
GCLC¼ glutamate cysteine ligase catalytic
subunit
GFP¼ green fluorescence protein
GSEA¼ gene set enrichment analysis
GSH¼ reduced glutathione




IVIS¼ in vivo imaging system




ROS¼ reactive oxygen species




PBST¼ PBS containing 0.1% Tween 20
PCR¼ polymerase chain reaction
shRNA¼ short hairpin RNA
siRNA¼ short interfering RNA
TBST¼Tris-buffered saline buffer
containing 0.1% Tween-20
TCGA¼The Cancer Genome Atlas
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